| 引用本文: | 张函舒,宋沧桑,李兴德,杨金伟,毛盼盼,王国徽,马雪娇.肾移植患者SLCO1B3基因多态性与他克莫司血药浓度相关性研究[J].中国现代应用药学,2023,40(23):3297-3300. |
| ZHANG Hanshu,SONG Cangsang,LI Xingde,YANG Jinwei,MAO Panpan,WANG Guohui,MA Xuejiao.Correlation Between SLCO1B3 Gene Polymorphism and Plasma Concentration of Tacrolimus in Renal Transplant Recipients[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(23):3297-3300. |
|
| 摘要: |
| 目的 探究肾移植患者SLCO1B3基因多态性与术后早期他克莫司血药浓度的相关性。方法 选取昆明市第一人民医院68例肾移植患者为研究对象，运用化学免疫发光法监测他克莫司血药浓度，同时采用聚合酶链反应法检测CYP3A5*3、SLCO1B3 T334G和G699A基因多态性，并进行基因分型，分析各基因型与他克莫司血药浓度的相关性。结果 CYP3A5*3不同基因型对术后他克莫司血药浓度和标准化血药浓度有影响，差异具有统计学意义(P＜0.05)，SLCO1B3 T334G和G699A基因位点不同基因型对术后他克莫司血药浓度和标准化血药浓度无影响，差异均无统计学意义。结论 与CYP3A5*3/*3基因型相比，CYP3A5*1等位基因携带者达到相同的他克莫司浓度需要增加他克莫司给药剂量。SLCO1B3 T334G和G699A基因多态性对肾移植术后早期他克莫司血药浓度无影响。 |
| 关键词: 肾移植 他克莫司 血药浓度 SLCO1B3 基因多态性 |
| DOI：10.13748/j.cnki.issn1007-7693.20224301 |
| 分类号:R969.4 |
| 基金项目:云南省器官移植临床医学中心开放课题(2020SYZ-Z-023)；云南省卫生健康委员会医学领军人才培养计划(L-2018012)；云南省临床药学中心建设项目；昆明市春城计划高层次创新创业团队专项(2022SCP002) |
|
| Correlation Between SLCO1B3 Gene Polymorphism and Plasma Concentration of Tacrolimus in Renal Transplant Recipients |
|
ZHANG Hanshu1, SONG Cangsang1, LI Xingde1, YANG Jinwei2, MAO Panpan1, WANG Guohui1, MA Xuejiao1
|
|
1.Department of Pharmacy, the First Hospital of Kunming, Kunming 650000, China;2.Affiliated Ganmei Hospital, Kunming Medical University, Kunming 650000, China
|
| Abstract: |
| OBJECTIVE To explore the correlation between SLCO1B3 gene polymorphisms and early postoperative tacrolimus concentrations in renal transplant recipients. METHODS A total of 68 patients who underwent kidney transplantation in the First Hospital of Kunming were selected, tacrolimus plasma concentrations were monitored by chemoluminescence, CYP3A5*3, SLCO1B3 T334G and G699A gene polymorphisms were detected by polymerase chain reaction, and genotyping was performed to analyze the correlation between each genotype and tacrolimus plasma concentrations. RESULTS Different genotypes of CYP3A5*3 had significant effects on postoperative tacrolimus plasma concentration and standardized plasma concentration(P＜0.05), and different genotypes of SLCO1B3 T334G and G699A gene loci had no significant effect on postoperative tacrolimus plasma concentration and standardized plasma concentration. CONCLUSION Compared with CYP3A5*3/*3 genotype, CYP3A5*1 allele carriers need to reach the same tacrolimus concentration to increase tacrolimus dose. SLCO1B3 T334G and G699A gene polymorphisms has no effect on tacrolimus plasma concentration in the early stage after renal transplantation. |
| Key words: renal transplant tacrolimus blood concentration SLCO1B3 polymorphisms |
